Anthropic acquires Mithril Medicine to run rare-disease drug programs
arthurcolle · x · 2026-10-28
Anthropic has acquired Mithril Medicine to run rare-disease programs, saying it wants to share its models with drug-development researchers and as many research organizations as possible. Commentators frame it as a one-person-biotech acqui-hire — a signal that frontier AI labs are moving directly into drug discovery rather than just selling API access to pharma.
More from Companies & People
- Ex-OpenAI researcher quips: who knew IMO Gold winners were so good at enterprise sales — willdepue · 2026-10-28
- OpenAI researcher mocks startups: IMO gold winners to resell tokens in a React app — willdepue · 2026-10-28
- GitHub Universe turns 12: Day 1 keynote kicks off tomorrow at 9 AM PT — film_girl · 2026-10-28
- NYT breaks down Anthropic's 335-page S-1: Spark Capital's $777M could become $10.9B at $1.5T valuation — nordicinst · 2026-10-28
- Re:Build CEO: robots attack a small slice of production cost, lean beats them — jaimalik · 2026-10-28
- Marc Andreessen on Replit: the dawn of the 'self-driving company' — amasad · 2026-10-28